Author

Qianqian Hu

University of South FloridaPrimary ORCID profile (0000-0002-8532-0622 · 2 papers)Unclaimed ORCID profile · follow to get notified of new preprints

Listed by name: these papers carry no ORCID for this author, so different people with the same name may be mixed together.

Same name, identified by ORCID

Qianqian HuiD2 papers · Hangzhou Normal University

Biology Disciplines

Click to filter author papers

Cancer Biology· 1

Signature Assays, Organisms & Methods

Click to filter · or open tag

Research Focus:cancer & tumor microenvironment· 1 Approach:experimental assay· 1 Approach:genetic perturbation / CRISPR· 1 Approach:microscopy & imaging analysis· 1 Organism:mouse· 1 Assay:proteomics· 1 Approach:wet-lab / biochemical assay· 1

Frequent Co-Authors

Andriy MarusykiD· 1 shared Bin FangiD· 1 shared Bina DesaiiD· 1 shared Daria MiroshnychenkoiD· 1 shared Eric A. WelshiD· 1 shared Eric B. HauraiD· 1 shared Gabriela M. WrightiD· 1 shared Jodi L. KroegeriD· 1 shared

Activity by Year

2025-2025 · peak 1/yr

Co-Author Collaboration Network

10 top collaborators · 45 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

1 shared paperCancer Biology

Andriy MarusykORCID

Mutual co-authors in cluster

Author profile →

1 paper

Recent·Most cited

Cancer BiologyScience SignalingPeer-reviewedDec 23, 2025

Cancer-associated fibroblasts confer ALK inhibitor resistance in EML4-ALK-driven lung cancer via concurrent integrin and MET signaling

Qianqian Hu, Lily L. Remsing Rix, Bina Desai…·Uwe Rix

This study identifies that CAFs confer ALK inhibitor resistance in EML4-ALK-driven lung cancer through both MET and integrin signaling pathways, and shows that targeting both pathways improves treatment efficacy.

6 citations

mouseproteomics